Pharmacotherapy:老年和肾病患者应用磺脲类低血糖风险高

2012-06-05 佚名 糖尿病手机报第14期

  美国一项巢式病例对照研究报告,在应用磺脲类的住院糖尿病患者中,高龄、肾小球滤过率低以及同时应用中长效胰岛素治疗者发生低血糖的风险高。研究5月8日在线发表于《药物治疗》(Pharmacotherapy)。   该研究纳入117例糖尿病住院患者和相同数量对照者。结果为,19%应用磺脲类治疗的患者至少经历1次低血糖事件,服用格列本脲、格列美脲和格列吡嗪者中分别有22%、19%和16%有低血糖发作。

  美国一项巢式病例对照研究报告,在应用磺脲类的住院糖尿病患者中,高龄、肾小球滤过率低以及同时应用中长效胰岛素治疗者发生低血糖的风险高。研究5月8日在线发表于《药物治疗》(Pharmacotherapy)。

  该研究纳入117例糖尿病住院患者和相同数量对照者。结果为,19%应用磺脲类治疗的患者至少经历1次低血糖事件,服用格列本脲、格列美脲和格列吡嗪者中分别有22%、19%和16%有低血糖发作。多因素回归分析显示,≥65岁(OR=3.07)、应用中长效胰岛素(OR=3.01)和肾小球滤过率(GFR)≤30 ml/(min·1.73 m2)(OR=3.64)为发生低血糖的预测因素。

  



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1738737, encodeId=e8a11e3873718, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Fri Apr 12 05:02:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025759, encodeId=d85d2025e5917, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Mar 03 14:02:00 CST 2013, time=2013-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787118, encodeId=b9531e87118a0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Sep 19 08:02:00 CST 2012, time=2012-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995873, encodeId=c1cd19958e3fb, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jun 23 07:02:00 CST 2012, time=2012-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908145, encodeId=da2319081456d, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Oct 12 07:02:00 CST 2012, time=2012-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442132, encodeId=61741442132a0, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1738737, encodeId=e8a11e3873718, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Fri Apr 12 05:02:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025759, encodeId=d85d2025e5917, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Mar 03 14:02:00 CST 2013, time=2013-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787118, encodeId=b9531e87118a0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Sep 19 08:02:00 CST 2012, time=2012-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995873, encodeId=c1cd19958e3fb, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jun 23 07:02:00 CST 2012, time=2012-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908145, encodeId=da2319081456d, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Oct 12 07:02:00 CST 2012, time=2012-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442132, encodeId=61741442132a0, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1738737, encodeId=e8a11e3873718, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Fri Apr 12 05:02:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025759, encodeId=d85d2025e5917, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Mar 03 14:02:00 CST 2013, time=2013-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787118, encodeId=b9531e87118a0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Sep 19 08:02:00 CST 2012, time=2012-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995873, encodeId=c1cd19958e3fb, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jun 23 07:02:00 CST 2012, time=2012-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908145, encodeId=da2319081456d, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Oct 12 07:02:00 CST 2012, time=2012-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442132, encodeId=61741442132a0, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=)]
    2012-09-19 jj000001
  4. [GetPortalCommentsPageByObjectIdResponse(id=1738737, encodeId=e8a11e3873718, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Fri Apr 12 05:02:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025759, encodeId=d85d2025e5917, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Mar 03 14:02:00 CST 2013, time=2013-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787118, encodeId=b9531e87118a0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Sep 19 08:02:00 CST 2012, time=2012-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995873, encodeId=c1cd19958e3fb, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jun 23 07:02:00 CST 2012, time=2012-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908145, encodeId=da2319081456d, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Oct 12 07:02:00 CST 2012, time=2012-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442132, encodeId=61741442132a0, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=)]
    2012-06-23 yb6560
  5. [GetPortalCommentsPageByObjectIdResponse(id=1738737, encodeId=e8a11e3873718, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Fri Apr 12 05:02:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025759, encodeId=d85d2025e5917, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Mar 03 14:02:00 CST 2013, time=2013-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787118, encodeId=b9531e87118a0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Sep 19 08:02:00 CST 2012, time=2012-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995873, encodeId=c1cd19958e3fb, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jun 23 07:02:00 CST 2012, time=2012-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908145, encodeId=da2319081456d, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Oct 12 07:02:00 CST 2012, time=2012-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442132, encodeId=61741442132a0, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1738737, encodeId=e8a11e3873718, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Fri Apr 12 05:02:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025759, encodeId=d85d2025e5917, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Mar 03 14:02:00 CST 2013, time=2013-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787118, encodeId=b9531e87118a0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Sep 19 08:02:00 CST 2012, time=2012-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995873, encodeId=c1cd19958e3fb, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jun 23 07:02:00 CST 2012, time=2012-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908145, encodeId=da2319081456d, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Oct 12 07:02:00 CST 2012, time=2012-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442132, encodeId=61741442132a0, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=)]

相关资讯

Blood:治疗慢性疾病和糖尿病伤口的新药物

近日,瑞典Ume?大学开发出了一个独特的新药物,该药物可以启动和加快糖尿病和其他慢性疾病的伤口愈合。这一药物是经过几年的实验研究而获得成功的,目前正准备进行临床试验。研究人员证实纤维蛋白溶酶原是一个触发炎症反应的启动和加速伤口愈合的关键调节因子,相关研究论文发表在Blood杂志上。 纤溶酶是一个众所周知的血浆蛋白,主要在肝脏中产生,在所有体液中都存在。Ume?研究人员现在重新评估纤溶酶的作用,揭

利拉利汀对非裔2型糖尿病患者安全有效

费城(EGMN)——一项纳入226例非裔2型糖尿病患者的多中心、随机、安慰剂对照试验显示,利拉利汀治疗与高血糖显著改善相关。    “非裔美国人一生中发生糖尿病的可能性增加77%,并且在临床试验中对降糖药物应答不佳,”美国小石城阿肯色糖尿病与内分泌中心的医学研究主管James R. Thrasher博士在美国临床内分泌医师协会年会上介绍,利拉利汀是一种每日用药1次的二肽基肽

AACE 2012:Resolute支架在糖尿病患者中的性能优

   在第21届美国临床内分泌医师协会年会(AACE2012, 5月23~27日, 美国费城)提交的一项新研究报告称,非胰岛素依赖型糖尿病患者置入Resolute佐他莫司洗脱冠脉支架2年后的安全性和功能预后与置入该支架的非糖尿病患者相似。此外,置入Resolute支架的胰岛素依赖型糖尿病患者的预后优于文献报道的置入其他药物洗脱支架(DES)的糖尿病患者。   今年3月,美国食品药品管理

IOVS:糖尿病药二甲双胍或可防治葡萄膜炎

5月7日,美国研究人员在美国《调查性眼科与视觉科学》(Investigative Ophthalmology & Visual Science)月刊上报告说,他们完成的动物研究显示,常用糖尿病药物二甲双胍可以预防并治疗常见的致盲疾病——葡萄膜炎。 得克萨斯大学研究人员给患有葡萄膜炎的小鼠喂食二甲双胍,小鼠炎症显著减轻;而在小鼠患病前喂食二甲双胍,则可起到预防作用。研究人员发现,二甲双胍的

童南伟:糖尿病领域重要的临床进展

   前言:在过去的2011年,国际糖尿病联盟(IDF)、美国内分泌医师协会(AACE)、中华医学会糖尿病学分会及内分泌学分会等组织,针对糖尿病的临床诊治、实验室检测及并发症的治疗等颁布了一些指南和共识;关于中国人糖尿病血管病变特点及糖尿病死因方面也有心得研究发布;同时,对于几种降糖药物的安全性问题,美国食品与药品管理局(FDA)和欧洲药品管理委员会(EMEA)也发布了声明。这些对于规范

Diabetes Care:二甲双胍联合利拉鲁肽+胰岛素序贯方案治疗2型糖尿病

  一项多国研究报告,在二甲双胍治疗血糖控制不佳的2型糖尿病患者中,序贯加用利拉鲁肽和地特胰岛素的强化治疗方案可被多数患者耐受,患者血糖控制佳、体重持续减轻且低血糖发生率低。研究5月14日在线发表于《糖尿病护理》(Diabetes Care)。   该研究纳入988例二甲双胍治疗血糖控制不佳的2型糖尿病患者,加用利拉鲁肽1.8mg/d治疗12周(导入期)后糖化血红蛋白(HbA1c)仍≥7%的患者